Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 30Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 18Lung Neoplasms 14Head and Neck Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Ovarian Neoplasms 7Carcinoma, Ovarian Epithelial 5Adenocarcinoma of Lung 5Inflammatory Breast Neoplasms 4Fallopian Tube Neoplasms 4Esophageal Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Salivary Gland Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms, Male 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Recurrent Uterine Corpus Sarcoma 2Recurrent Squamous Cell Lung Carcinoma 2Carcinoma 2Anatomic Stage I Breast Cancer AJCC v8 2Adenocarcinoma Of Esophagus 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1

Interventions

Docetaxel 1AZD4547 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × FGFR1 Gene Amplification × Docetaxel × Clear all
NCT02965378 2021-05-27

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Phase 2/3 Completed
43 enrolled 15 charts

FGFR1 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡